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Abstract
MITOSTATIN, a novel putative tumor suppressor gene induced by decorin overexpression, is expressed in most normal
human tissues but is markedly down-regulated in advanced stages of mammary and bladder carcinomas. Mitostatin
negatively affects cell growth, induces cell death and regulates the expression and activation levels of Hsp27. In this study,
we demonstrated that ectopic expression of Mitostatin in PC3, DU145, and LNCaP prostate cancer cells not only induced a
significant reduction in cell growth, but also inhibited migration and invasion. Moreover, Mitostatin inhibited colony
formation in soft-agar of PC3 and LNCaP cells as well as tumorigenicity of LNCaP cells in nude mice. Conversely, targeting
endogenous Mitostatin by siRNA and anti-sense strategies in PC3 and DU145 prostate cancer cells enhanced the malignant
phenotype in both cell lines. In agreement of these anti-oncogenic roles, we discovered that Mitostatin was absent in ,35%
(n=124) of prostate tumor samples and its overall reduction was associated with advanced cancer stages. Collectively, our
findings indicate that MITOSTATIN may acts as a tumor suppressor gene in prostate cancer and provide a novel cellular and
molecular mechanism to be further exploited and deciphered in our understanding of prostate cancer progression.
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Introduction
Prostate cancer is the main cause of cancer-related death in men
in most developed countries, and the most common malignancy in
American males. In the United States, one over eight men will
develop prostate cancer during his life and over 27,360 men are
expected to die from the disease this year [1].
Molecular genetics studies of prostate cancer have identified
mutations, deletions, or loss of tumor suppressor genes expression
in subsets of patients with prostate cancer [2]. However, due to the
heterogeneity of prostate cancer itself and the focal nature of
oncogene/tumor suppressor gene alterations, the role of these
genes in prostate cancer onset and the diagnostic and/or
prognostic value of such genes alterations remains uncertain [2].
Loss of heterozygosity (LOH) points out the presence of
suppressor genes at specific chromosomal regions in tumors.
Several allelotyping studies reported the telomeric portion of
chromosome 12 to be deleted in a variety of solid tumors [3–11],
including prostate cancer [12].
MITOSTATIN is a novel putative tumor suppressor gene
localized at 12q24.1 [13–15] recently characterized in our
laboratory [13]. We have previously demonstrated that this
decorin-induced 62-kDa protein is expressed in most human
tissues; it affects prostate cancer cell growth and cell death by
regulating the level and activation of Hsp27 [13]. We have also
analyzed by immunohistochemistry the expression of Mitostatin in
a series of primary bladder and breast tumors, and observed a
reduction of Mitostatin protein levels in advanced tumor stages. In
addition, Kim and colleagues have recently identified a frameshift
mutation of MITOSTATIN gene in a gastric carcinoma with
microsatellite instability [14].
Although the biological function of Mitostatin in prostate
cancers is not yet characterized, its relationship to decorin and
Hsp27 suggests a role for Mitostatin in cancer development. To
study the tumor suppressor function of Mitostatin in prostate
cancer, we over-expressed and depleted endogenous Mitostatin
protein by antisense and siRNA strategies in prostate cancer-
derived cell lines.
In this study, we provide the first evidence for a role of
Mitostatin in inhibiting cell migration, invasion and tumorigenicity
of prostate cancer cells. Furthermore, our data indicate that
Mitostatin is down-regulated in advanced stage human prostate
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19771cancers. Thus, Mitostatin could act as a classical tumor suppressor
gene and analysis of its expression may prove a useful clinical
marker for diagnosis and prognosis in this common human cancer.
Results
Mitostatin Over-expression in Prostate Cancer Cells
Inhibits Colony Formation
As an initial approach to establish Mitostatin expression in
prostate we utilized cell extracts from fourteen different prostate-
derived cells, including both normal and malignant prostatic cells.
Using immunoblotting with a Mitostatin-specific antibody [13], we
discovered that all cell lines analyzed, but one (i.e.: 1542CP3TX),
expressed Mitostatin protein at various levels (Figure 1A). Notably,
LNCaP cells displayed the highest expression and 1532CP2TX
showed a barely-detectable levels of endogenous Mitostatin
(Figure 1A). Of note, 1542NPTX cells, which express Mitostatin,
are the ‘‘normal’’ counterparts of the Mitostatin-negative malig-
nant 1542CP3TX cells.
Next, we focused on investigating the biological function of
Mitostatin in prostate cancer cells by stably transfecting PC3 and
LNCaP cells with a V5-tagged Mitostatin cDNA expression
construct and PC3 and DU145 cells with an anti-sense cDNA
construct. We also placed the Mitostatin coding sequence in a self-
inactivating retroviral vector under the control of an inducible
Drosophila HPS70 promoter to infect DU145 cells. We obtained
five clones stably over-expressing Mitostatin (PC3 B2, DU145
Mitostatin, LNCaP B1A, LNCaP B3A and LNCaP A3A) and two
clones which showed decreased levels of endogenous Mitostatin
protein (PC3 M2 and DU145 M2) (Figure 1B). In three
independent colony formation assays, all Mitostatin-overexpress-
ing cell lines showed a decrease in the number and size of colonies
after 15 days (Figure 2 A–C) as compared to either the parental or
the V5-transfected cells. DU145 Mitostatin, which is also the clone
with the highest expression of Mitostatin compared to parental cell
expression (4.2 fold increase, cfr Figure 1B), showed the highest
inhibition of colony formation (Figure 2 B). Of interest, cells
expressing a Mitostatin antisense construct showed either a similar
(DU145 M2, Figure 2 B) or higher (PC3 M2, Figure 2A) number
of colonies in comparison to the parental or mock transfected cells.
Mitostatin Over-expression Inhibits Migration of Prostate
Cancer Cells
It is well established that decorin and Hsp27 are involved in cell
migration. The former has been shown to exert an anti-migratory
effect in various cell lines involving different signaling pathways
[16–19], whereas the latter is involved in the actin reorganization
when cells form lamellipodia [20]. Since we have previously
discovered Mitostatin in decorin-over-expressing cells and dem-
onstrated that Mitostatin inhibits the expression and phosphory-
lation of Hsp27 in prostate cancer cell lines [13], we sought to
determine whether Mitostatin may regulate cell migration in
prostate cancer cells. Consequently, we conducted in vitro
migration assays using the various Mitostatin-overexpressing or
Mitostatin-depleted prostate cancer cells. In all cell line tested,
Mitostatin over-expression inhibited the ability of cells to migrate
(Figure 3A) indicating that Mitostatin negatively regulates
migration of prostate cancer cells. In Mitostatin-over-expressing
LNCaP clones the inhibitory effect of Mitostatin on migration was
directly correlated to the amount of protein (i.e.: LNCaP A3A
clone with the highest Mitostatin expression was the slowest in the
migration assay). Conversely, prostate cancer cells in which
endogenous Mitostatin was down-regulated by either antisense
strategy (PC3 M2 and DU145 M2) or Mitostatin siRNA (PC3
cells) showed increased cell motility (Figures 3A).
Next, we determined the ability of Mitostatin to inhibit
migration of prostate cancer cells using an in vitro ‘‘wound-
healing’’ motility assay [21]. In contrast to parental cells and PC3
V5 control cells (data not shown), PC3 B2 cells over-expressing
Mitostatin showed a substantial decrease in migration into the
denuded area, both at 4 and 8 hours after the wounding
(Figure 3B). We performed the same experiment on LNCaP and
DU145 cells and observed that in all cell lines. Essentially,
Figure 1. Mitostatin expression in prostate cancer cell lines. A: Western blot analysis: Mitostatin is differentially expressed in human prostate
cancer cell lines. Protein loading was confirmed by reprobing the membrane with antibody to b-actin. B: Western blots showing the expression of
Mitostatin in PC3, DU145 and LNCaP cell lines utilized in this study.
doi:10.1371/journal.pone.0019771.g001
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compared to parental or mock-transfected cells (data not shown).
Mitostatin Over-expression Inhibits Invasion and Cell
Adhesion
The acquisition by cancer cells of an invasive phenotype is a
critical step for tumor progression. Matrigel-coated filters are
widely used to examine invasive migration through a three-
dimensional extracellular matrix [21]. Consequently, we conduct-
ed in vitro invasion assays evaluating the ability of prostate cancer
cells to invade through Matrigel in 5% serum-containing medium.
Mitostatin over-expression inhibited cellular invasion in all cell
lines tested (Figure 4A). In LNCaP over-expressing clones the
inhibitory effect of the protein on migration was directly correlated
to the amount of protein (LNCaP A3A had the lowest capability to
invade). Moreover, we observed an increased in cell invasion in
PC3 M2 and DU145 M2 antisense clones, and PC3 Mitostatin
siRNA cells.
Adherence to extracellular matrix is an intrinsic characteristic of
an invasive and metastatic phenotype and migrating cells form
transient attachments to the extracellular matrix. Notably,
laminin-1 is the major component of Matrigel. Therefore, we
performed adhesion assays and plated the various Mitostatin-
overexpressing or Mitostatin-depleted prostate cancer cells on
laminin-coated plates. Cells were allowed to adhere to laminin for
2 hours and the number of attached cells was then calculated. The
number of cells that adhered to laminin was significantly lower in
cells over-expressing Mitostatin as compared to parental cells in
DU145 and PC3 cell lines (Figure 4B), indicating that Mitostatin
inhibits cell adhesion to laminin. In agreement with this
conclusion, Mitostatin-depleted PC3 cells showed an increased
capacity to adhere to laminin (Figure 4B). On the other hand, the
lack of significant differences in cell adhesion to laminin observed
in the LNCaP cells could be partly explained by their documented
low adhesive ability in vitro [22,23].
Collectively, our results suggest that Mitostatin not only inhibits
the migratory ability of prostatic cancer cells but also the ability to
invade a complex three-dimensional matrix, such as Matrigel, and
to adhere to laminin substrata.
Mitostatin Over-expression Inhibits Anchorage-
independent Growth and Tumorigenicity
To further investigate the hypothesis that Mitostatin may play a
direct role in prostate carcinogenesis, we performed anchorage-
independent growth assays and an in vivo tumorigenicity assays in
nude mice. PC3 B2 cells with high Mitostatin expression did not
form colonies, whereas PC3 M2 with low Mitostatin level showed
an increased number of colonies (Figure 5A). Furthermore, the
majority of the colonies in the PC-3 M2 cells were larger than
those in control cells (data not shown). In LNCaP cells (Figure 5A–
B), the reduction in the number and dimension of the colonies
directly correlated with Mitostatin expression levels.
Figure 2. Mitostatin expression affects colony formation of prostate cancer cells. Mitostatin over-expression in prostate cancer derived cell
lines [PC3, A; DU145, B; and LNCaP, C] decreased the ability to form colonies after 15 days, while cells with depletion of endogenous Mitostatin
protein showed a similar (DU145 M2) or higher (PC3 M2) number of colonies compared to parental cells. Columns, average per dish from triplicate
experiments; bars, SEM. * P,0.05; ** P,0.01.
doi:10.1371/journal.pone.0019771.g002
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over-expressing LNCaP cells were significantly smaller than those
induced by LNCaP parental cells and LNCaP V5 control cells
(Figure 6A–B). Tumors derived from LNCaP B1A and LNCaP B3A
reached an average volume 50% and 25% smaller than the tumors
derived from parental cells. Immunohistochemical analysis of
paraffin-embedded tumors and immunoblot analyses of frozen tumor
xenografts (Figure 6C–D) showed high Mitostatin expression in
LNCaP B1A and LNCaP B3A xenografts, compared with basal level
of Mitostatin expression shown in parental cells. Mitostatin expression
in transfected cells was additionally confirmed by immunohistochem-
ical analyses using the anti-V5 tag antibody (Figure 6C).
Collectively, these findings indicate that Mitostatin is directly
involved in a dose-dependent fashion in controlling one of the
most powerful in vitro properties of malignant cells, such as
anchorage independent growth, as well as in vivo tumorigenicity.
Thus, Mitostatin is a key negative regulator of the transformed
phenotype in prostate cancer.
Mitostatin Expression is Decreased in Advanced Prostate
Carcinomas
We have recently shown that Mitostatin is ubiquitously expressed
in normal human tissues, but its levels are markedly attenuated in
advanced stages of breast and bladder cancers [13]. To investigate
Mitostatin expression in prostate cancers, we evaluated by qRT-
PCR analysis 10 matched normal-cancer samples and by
immunohistochemistry (IHC) three tissue microarrays composed
of 293 specimens including 124 prostate cancers and 43 normal
counterparts. Mitostatin mRNA levels were significantly down-
regulated in the cancerous counterpart (Figure 7A; P=0.029). This
data was further confirmed by IHC. Mitostatin was expressed
mainly in the cytoplasm of the basal cell layer of the normal
prostatic epithelium (Figure 7B) and a strong positivity wasobserved
in the so called prostatic gland atrophy (Figure 7C). All the pre-
Figure 3. Mitostatin inhibits in vitro migration of prostate
cancer cells. A and B: Mitostatin over-expressing clones showed
reduced migratory properties compared to parental cells. Migration was
assessed through migration (A) and the wound healing assays (B). Cells
with down-regulation of the endogenous Mitostatin protein (PC3 M2,
PC3 Mitostatin shRNA, and DU145 M2) showed an increased malignant
behavior. Data are expressed as percentage of migration versus parental
cells. Columns, representative images of triplicates from three
independent experiments; bars, SEM. * P,0.05; ** P,0.01.
doi:10.1371/journal.pone.0019771.g003
Figure 4. Mitostatin inhibits in vitro invasion and adhesive
properties to laminin of prostate cancer cells. A: Mitostatin
inhibits invasive properties of prostate cancer cells. Cells with down-
regulation of the endogenous Mitostatin protein (PC3 M2, PC3
Mitostatin shRNA, and DU145 M2) showed an increased malignant
behavior. B: Mitostatin over-expression affects cell ability to attach to
laminin. Data are expressed as percentage of migration versus parental
cells. Columns, representative images of triplicates from three
independent experiments; bars, SEM. * P,0.05; ** P,0.01.
doi:10.1371/journal.pone.0019771.g004
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immunostaining (Figure 7D), whereas most of the adenocarcinoma
showed either focal staining (Figure 7E, F) or no staining at all
(Figure 7G). As expected, muscle cells and blood vessels’ endothelia
showed a Mitostatin moderate positivity. Of interest, five neoplastic
cases had exclusively nuclear positivity. In total, 44 of the 124 tumor
samples were totally negative (,35%), 65 showed a mild to medium
positivity (52.4%) and only 15 samples showed strong Mitostatin
positivity (12.1%). In the univariate analysis, a decreased Mitostatin
immunohistochemical score correlated with tumor stages
(P=0.046), pT increase (P=0.040), and tumor volume
(P=0.045). No clinical-pathological parameters resulted indepen-
dently statistically significant associated to Mitostatin expression in
the multivariate analysis. These findings further corroborate the
notion that loss of Mitostatin through mutations or protein
degradation could contribute to prostate cancer progression insofar
as the prostate cancer specimens evaluated above derive from
advanced prostate cancer patients.
Discussion
Although prostate cancer is one of the most common
malignancies, very little is known about the molecular mechanisms
that determine malignant transformation of the prostatic epithe-
lium. During prostate cancer progression, tumor cells become
more motile and acquire invasive capacity. Most deaths from
prostate cancer are not due to the primary tumor but rather to
secondary metastases to distant organs. For this reason it is of
fundamental importance to study the mechanisms that drive
prostate cancer invasion and metastases. The chromosomal region
12q has been demonstrated to be deleted in a large variety of solid
advanced tumors [3–12], hence suggesting the presence, in this
region, of one or more tumor suppressor genes involved in the
process of cancer progression.
We have previously identified the Mitostatin gene, localized at
12q24.1, in the process of screening for growth-arrested genes
induced by the leucine-rich proteoglycan decorin [13]. Decorin is
a member of the small leucine-rich proteoglycan gene family that
has recently become a focus in several areas of cancer research
[20]. This soluble protein is involved in a number of cellular
processes including matrix assembly, fibrillogenesis, and the
control of cell proliferation [18,24–33]. Decorin has been shown
to inhibit migration [16–19,34], invasion [18], and tumorigenicity
[19,29,33,35,36] of a wide variety of transformed cells. Moreover,
decorin induces apoptosis through the activation of caspase-3
[36,37]. Hence, it is plausible, that decorin-induced proteins could
be effectors of the tumor suppressive action of this proteoglycan.
We have previously shown that Mitostatin is ubiquitously
expressed in normal human tissues. However, its protein levels are
markedly attenuated in advanced stages of primary mammary and
urothelial neoplasms [13]. We further demonstrated that Mitos-
tatin over-expression negatively affects cell growth and induces cell
death in bladder cancer cell lines [13], suggesting that Mitostatin
could behave as a classical tumor suppressor gene in other forms of
malignancy. In the present study we utilized three widely used
prostate carcinoma cell lines, namely, PC3 and DU145 castration-
resistant cells, and LNCaP androgen-dependent cells, and utilized
transgenic and immunological strategy to pinpoint the function of
Mitostatin in these cells. Our results confirmed our prediction of
Mitostatin belonging to the tumor suppressor gene family insofar
as overexpression of Mitostatin inhibited colony formation,
whereas suppression of endogenous Mitostatin caused the opposite
effects.
Cell migration and invasion are fundamental components of
tumor cell metastases. As increased cell migration and invasion are
hallmarks of the metastatic phenotype, and thus a measure of
aggressiveness, the current study provides results that implicate
Mitostatin as an important protein for determining an aggressive
cellular phenotype. Indeed, Mitostatin over-expressing clones
showed a significant decrease in motility, and vice-versa by down-
regulating endogenous Mitostatin with either antisense or siRNA
strategies we triggered the opposite result. A direct role of
Mitostatin in promoting cellular migration is also evident from our
wound-healing studies, confirmed in all cell lines analyzed.
Our results demonstrate that Mitostatin regulates both cellular
motility and the ability of prostate cancer cells to invade through a 3D
matrix via a mechanism yet to be elucidated. Mitostatin altered the
cell adhesion properties to laminin, which is the first necessary step to
invade the Matrigel membrane. This finding is consistent with the
role that decorin plays as a negative regulator of cell adhesion to
laminin [19]. Other tumor suppressor genes have been shown to
affect multiple cancer cells characteristics (migration, invasion,
growth, predisposition to apoptotic stimuli) acting on important
cellular protein complexes [38–40]. Thus, our future efforts will be
focused on identifying Mitostatin protein’s partners and on studying
the possible cascade signals implicated in Mitostatin biology.
To investigate a possible direct role for Mitostatin in prostate
cells transformation we performed anchorage-independent growth
assays and an in vivo tumorigenicity in nude mice. Both studies
confirmed the role of Mitostatin as a negative regulator of
Figure 5. Mitostatin affects anchorage-independent growth of
prostate cancer cells. A: Data from triplicate cultures of parental PC3
and LNCaP, and clones PC3 V5, PC3 B2, PC3 M2, LNCaP V5, LNCaP B1A,
LNCaP B3A, and LNCaP A3A plated in soft-agar generating colonies
larger than 0.2 mm in diameter. Clones over-expressing Mitostatin
showed a decreased ability to form colonies, while the Mitostatin down-
regulated clone, PC3 M2, showed a higher number of colonies
compared to parental cells. Colonies were counted after 21 days.
* P,0.05; ** P,0.01 B: Representative colonies of LNCaP parental cells
(left), LNCaP B1A (middle), and LNCaP A3A (right) are shown after 21
days (magnification 6200).
doi:10.1371/journal.pone.0019771.g005
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lated well with the aggressiveness of cancer cells.
In this study we observed a reduction in Mitostatin expression in
two prostate cancer-derived cell lines (1542CP3TX and
1532CP2TX; 16.7% of the cancer-derived cell lines) and in
,35% of a series of 124 prostate cancers. Of interest, in normal
samples, the upper epithelial prostatic layer was consistently
negative for Mitostatin epitopes, whereas the lower layer showed a
strong positivity, suggesting the presence of a different cellular
commitment in Mitostatin expression. A strong positivity was
always observed in the so called prostatic gland atrophy (a
common process typically but not exclusively found in older
patients), while a moderate positivity was observed in all the pre-
neoplastic lesions, with a decrease in the most advanced prostate
cancer stages. In primary prostate tumors, Mitostatin down-
regulation was statistically associated with advanced tumor stages
and increased size (or direct extent) of the primary tumor at
pathological examination (i.e.: pT), confirming our previous
observation in breast and bladder cancer [13]. These results
suggest that down-regulation of Mitostatin during the later stages
of prostate tumorigenesis could promote cancer progression. We
did not find any correlation between Mitostatin expression and
other clinical parameters used to assess prostate cancer poor
prognosis, such as Gleason grade, though this point remains to be
investigated in a larger series of cases.
In conclusion, the present study provides the first evidence that
Mitostatin might play a significant role as tumor suppressor in
prostate tumor development and progression through its inhibitory
effects on cell migration, invasion, anchorage-independent growth,
and in vivo tumorigenesis. Moreover, Mitostatin level is decreased
in advanced stages of primary prostate cancers. Taken together,
these data further support the hypothesis that Mitostatin acts as a
bona fide tumor suppressor and suggest that further investigations of
Mitostatin as a useful clinical marker for diagnosis and prognosis
in prostate tumors are warranted.
Materials and Methods
Cell Culture and Generation of Stable Clones
Prostate cancer derived cell lines 2220, 2221, 11609, 11610,
11611, TSUP, 1532CP2Tx, 1535CP1Tx, 1542CP3Tx, LNCaP,
DU145, and PC3 and prostate immortalized normal derived cell
lines 1535NPTX, and 1542NPTX were obtained from American
Type Culture Collection (ATCC, Manassas, VA) and maintained
as recommended. Cells were transfected as previously described
[13,41] (Data S1), and selected in medium supplemented with
either G418 (400 mg/ml) or puromycin (0.75 mg/ml) for 3 weeks.
Mitostatin Gene Silencing
Gene silencing of human Mitostatin was achieved by siRNA
strategies using validated SureSilencing Mitostatin siRNA and
control plasmids (SuperArray Bioscience Corp, Frederick, MD).
PC3 cells were transfected with vehicle (DEPC-treated water),
control siRNA (scrambled), or siRNA directed against Mitostatin
(100 pmol/L) using Oligofectamine
TM reagent (Invitrogen, Carls-
bad, CA) following manufacturer’s protocols. Twenty-four hours
after transfection, PC3 cells were starved in serum-free medium
(SFM) for 12 hours and then were processed and analyzed for
Figure 6. Effects of Mitostatin over-expression on the LNCaP
cell tumorigenicity in nude mice. A: Xenografts established by sub
cutaneous injection of LNCaP, LNCaP V5, LNCaP B1A and LNCaP B3A
cells in athymic (BALB/c nu/nu) were grown for 65 days. B: Tumor
volume in animals injected with cells over-expressing Mitostatin was
markedly decreased compared to tumors in animals injected with
control cells. The graph illustrates the distribution in tumor sizes formed
in BALB/c nu/nu mice through 65 days. *: P,0.05. C, D: Immunohis-
tochemical and immunoblot analysis of Mitostatin expression in LNCaP
and derivative tumor xenografts. Immunohistochemistry was per-
formed using both anti-V5 (upper panels) and anti-Mitostatin (lower
panels) antibodies. Scale bar: 50 mm.
doi:10.1371/journal.pone.0019771.g006
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Mitostatinprotein wasdetected by immunoblot analysis (Figure S1).
Colony Formation and Migration Assays
Cells were plated at a density of 400 cells/100 mm dish. On day
15, cells were fixed in 10% formalin [100% formaldehyde is 37%,
thus 3.7% is 10% formalin, i.e.: PBS-formaldehyde] and stained
with crystal violet for colony counting [21]. Cells were serum
starved for 24 hours. Cells (2.5610
4 in 200 ml) were then seeded in
Boyden chambers (upper chamber) (BD Biocoat, Bedford, MA).
Lower chambers contained 500 mL of either SFM or 1% or 5%
serum. After 10 hours, migrated cells were counted under the
microscope after fixing and staining in Coomassie blue as
described [42,43].
Migration, Invasion and Adhesion Assays
Cells were seeded onto 35-mm plates in serum-containing
medium until sub-confluence and then transferred to SFM. After
24 hours, the plates were scratched with a thin disposable tip to
generate a wound in the cell monolayer [42]. Cells were incubated
for additional 72 hours in 1% or 5% serum-containing medium
and analyzed and photographed with a Zeiss Axiovert 200 M cell
live microscope (Carl Zeiss Inc., Thornwood, NY) using the
Metamorph Image Acquisition and Analysis software (Universal
Imaging, Downingtown, PA) at the Kimmel Cancer Center
Confocal Microscopy Core Facility. Cell invasion through a three-
dimensional extracellular matrix was assessed by a Matrigel
invasion assay using BD Matrigel Invasion Chambers (BD
Biocoat) with 8.0-mm filter membranes as previously described
[42,43]. For adhesion assays, 96-well plates, coated with mouse
laminin (BD Biocoat), were incubated at room temperature for
1 hour with 1% bovine serum albumin (BSA) (Sigma, St. Louis,
MO), to block unspecific binding. 100,000 cells/well were seeded
in triplicates and allowed to adhere for 2 hours at 37uC and non-
adherent cells were then removed with two washes. Adherent cells
were stained with CyQUANT NF Cell Proliferation Assay kit
(Invitrogen) and the absorbance was read at 490 nm. Background
levels of cell adhesion in wells coated with BSA alone were
subtracted from values obtained for laminin.
Anchorage-independent Growth and Tumorigenicity
Assays
For soft agar assay, cells were suspended in 0.2% agarose in
DMEM 10% FBS medium, plated at a density of 10
3 cells in a 60-
mm dish coated previously with 0.4% agarose, and maintained at
37Cu. On day 21, colonies .0.2 mm in diameter were counted
and analyzed [21]. Tumorigenicity assays were carried out
essentially as described [44], under protocols approved by the
Thomas Jefferson Animal Care and Use Committee. Immunode-
ficient, athymic nude (BALB/c nu/nu) mice were injected sub-
cutaneously into posterior flanks with 2610
6 cells in 200 mlo f
Matrigel basement membrane matrix (BD Biosciences). Tumor
growth was monitored daily for 65 days.
Ethic statements
All patients involved in the qRT-PCR study gave their written
informed consent. All human samples used in the immunohisto-
chemical study were purchased from Pentagen Inc. (Seoul, Korea),
which has the require permissions and patients’ consents. The
University of Padova and the Thomas Jefferson University
institutes’ ethical regulations on research conducted on human
tissues were followed.
Reverse Transcription and Quantitative Real Time PCR
A total of 10 cases of Gleason 7 (3+4) prostate cancers were
retrieved from the archives of the Surgical Pathology &
Cytopathology Unit of the University of Padova. In each case,
two 2-mm tissue cores were obtained from the macrodissected
paraffin blocks from the tumor and from the adjacent non-
cancerous prostatic tissue. The tissue cores were deparaffinised
with xylene at 50uC for 3 min. Total RNA was extracted using the
RecoverAll kit (Ambion, Austin, Texas, USA). Reverse Transcrip-
tion was performed using 100 ng of total RNA, M-MLV Reverse
Transcriptase (Invitrogen) and 250 mM random primers (Invitro-
gen). Quantitative Real Time PCR analyses were performed with
the LightCycler 480 Real-Time PCR System (Roche Diagnostics,
Mannheim, Germany). Experiments were performed according to
a standard protocol using the LightCycler 480 Probes Master
(Roche). B2M was included as housekeeping gene control to
correct for equal RNA amounts. Primer sequences and respective
probes were designed using the Universal ProbeLibrary (Roche)
and the ProbeFinder software (http://www.roche-applied-science.
com/): Mitostatin forward 59-GGG GGA CTC TTC GGA AAC-
39, Mitostatin reverse 59TGT CGT GCT AGC TGC TGA TT-
39; B2M forward 59-CCT TGA GGC TAT CCA GCG TA-39,
B2M reverse 59-TCA GGA AAT TTG ACT TTC CAT TC-39.
All the reactions were run in triplicate, including no-template
controls.
Figure 7. Mitostatin is down-regulated in human prostate cancers. A: Relative fold of Mitostatin mRNA levels in normal prostatic tissue
samples (N, black), and Gleason 7 prostate cancer samples (K, bright gray). Mitostatin showed a consistent down-regulation in cancer tissues
(P=0.029). Columns, representative images of triplicates; bars, SD. B–G: Immunohistochemical detection of Mitostatin in human prostate. Mitostatin
protein is localized in the cytoplasm of normal (B) and atrophic (C) prostatic glands. Higher levels of Mitostatin protein were observed in PIN lesions
(D) and in some tumors (E). F: In addition to a weak staining, Mitostatin was also detected in the nuclei in few cases of adenocarcinoma. G: Mitostatin
expression is present in an atrophic gland (black arrow) in contrast with the surrounding negative neoplastic glands. Scale bar: 50 mm.
doi:10.1371/journal.pone.0019771.g007
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Protein extraction and immunoblot analyses were performed as
described previously [13,21,43] (Data S1). Anti-Mitostatin [13]
1:1,000 and anti-b-actin 1:10,000 (Sigma) were used as primary
antibodies. Immunohistochemistry was performed as previously
described [13,21] (Data S1). Sections were immunostained
overnight at room temperature with a 1:100 dilution of the anti-
Mitostatin antibody or pre-immune serum as control. AccuMax
Array (Petagen Inc.) A222, A223 and A302 including 293 0.6-mm
cores were utilized for the immunohistochemical study. Samples
contained on the Array were derived from Korean patients and
clinical pathological information was also provided. All sections
were examined independently by two investigators (R.B., M.G.),
and complete agreement was reached for Mitostatin positivity and
negativity. Regarding the morphology and the intensity of
Mitostatin expression, positive staining of anti-Mitostatin antibody
was semiquantified with a three-tier system (0=negative;
1+=mild to moderate immunoreactions; 2+=strong immunore-
actions).
Statistical Analysis
Statistical analysis was carried out with SigmaStat for Windows
version 3.10 (Systat Software Inc., Point Richmond, CA). All
values were expressed as mean 6 SE or SD. Differences between
means were evaluated with double-sided Z-test. The x
2 test was
used to examine the categorical variables and the association
between Mitostatin immunohistochemical expression levels and
other clinico-pathological variables in univariate analysis. To
identify variables independently associated to Mitostatin immu-
nohistochemical levels, backward selection multivariate analysis
was performed using the logistic regression model. Differences
were considered statistically significant at P,0.05.
Supporting Information
Figure S1 Depletion of endogenous Mitostatin in PC3
cells. Gene knockout for MITOSTATIN was achieved by
siRNA. Twenty-four hours after transfection, PC3 cells were
serum stared for 24 hours and processed and analyzed for
migration and invasion. The expression of Mitostatin protein
was detected by immunoblot using anti-Mitostatin antibody.
Protein loading was normalized using anti-b-actin polyclonal
antibodies.
(TIF)
Data S1
(DOC)
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